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Mohammad Abdollahi1*, Armen Yuri Gasparyan2,3 and Soodabeh Saeidnia4In the era of “big science”, all researchers, academics and
students are under pressure to publish more and to report
more research activities for successful grant applications,
academic promotion, and course graduation. To meet the
ever-increasing publication activities, thousands of new
publishers have sprung up globally, and the number of on-
line and subscription journals has increased exponentially.
At the same time, temptation to publish more at all
costs has led to epidemics of unethical conduct and inev-
itable retractions, which question the validity of current
evidence-base [1]. Reasons for retractions include, but not
limited to fraud, plagiarism, multiple submissions and
duplicate publications, violation of copyrights and ethical
norms of research, and inappropriate authorship [2]. Un-
covered cases of misconduct and violation of publication
ethics are increasing at rapid pace due to the digitization
and open access movement in the last two decades [1].
And it is expected that the landscape of publications and
their indexing and citation records in bibliographic data-
bases will change substantially in the coming years.
Large amount of funding for research, publishing and
archiving activities comes from pharmaceutical agencies,
supporting individuals and their research and academic
institutions. Too often, pharmaceutical agencies hire
medical writers and professional experts for writing
research reports and guidelines on drugs and medical
technologies produced or promoted by the agencies.
Informing readership about relationships between authors
and pharmaceutical agencies is an ethical obligation, which
should be regarded for the sake of transparency and safety
of patients [3,4]. Non-disclosure of relevant relationships
with pharma is a misconduct with far-reaching healthcare
consequences that cannot be avoided even after corrections
or retractions of unethical publications. The authors have
to explicitly disclose any conflict at the manuscript sub-
mission by filling the structured form provided by the
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unless otherwise stated.Global editorial associations keep a close eye on research
and publication misconduct. For example, the Committee
on Publication Ethics (COPE) has a collection of appalling
cases of misconduct, which may help avoid similar cases
by improving awareness among young and seasoned re-
searchers, authors, reviewers, and editors [6]. Responsibil-
ity for accurate and unbiased research reporting lies not
only with authors, but also with all other stakeholders of
scientific communications. Research and academic institu-
tions are obliged to educate their authors and to inform
about publishing ethics and consequences of biased and
fraudulent publications. Reviewers and science editors, in
turn, have to carefully evaluate correctness of research
data and transparency of authorship, contributorship, and
disclosures of ethical approvals, funding, and conflicts
of interests. Ethical concerns may arise at any point
throughout the manuscript processing or post-publication,
and if so, responsible evaluators have to consult relevant
guidelines of COPE and act accordingly [7]. Each case of
misconduct should be discussed in a collegiate way with all
stakeholders of research publications to avoid similar cases
in the future.
Research misconduct may take a variety of forms,
which can be minor or major. The U.S. National Science
Foundation distinguished the following types of research
misconduct: fabrication (reporting made-up results), falsifi-
cation (manipulation of the research materials, equipment,
or processes), and plagiarism (utilizing someone else’s text
or ideas without appropriate crediting) [8,9]. Perhaps the
most important point here is the intention, which leads
to the misconduct and unethical publication (Figure 1).
Intentionally misleading readership by plagiarizing large
parts of previous publications, presenting fabricated
data, or omitting key negative data are matters of gross
misconduct, which require proper actions by reviewers,
editors, and publishers. Misinterpretation of statistical
data and omission of data on adverse effects of drugs
are also unethical acts, misleading non-expert readership
[10]. Minor forms of misconduct are text recycling due to
poor language skills or “academic laziness”, which often
stem from the urge to publish more, and can be prevented
by sharpening language skills and properly organizing theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Types of research misconduct by the U.S. National Science Foundation, which may take place as a consequence of the urge
to publish more.
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requires manuscript withdrawal or retraction depends on
the intention and several other factors. In any case, relying
on available guidance from COPE may help reach an
ethically acceptable decision [11,12].
Current “obsession” with impact factors and individual
impact indicators has led to the urge to produce moreFigure 2 Consequences of the urge to publish more and the role of e“groundbreaking” research data and target high-ranking
scholarly journals. Authors, who publish in high-impact
periodicals, are likely to attract more citations and se-
cure more funding from grant holders. The wealthiest
research grant providers prioritize widely-visible and
most-impacting publications, thus forcing researchers
and their institutions to publish more in top journalsvaluators.
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Science, Nature, Cell, and others primarily suffer from
fraudulent and unethical publications, eventually sub-
jected to retractions [1].
At the other extreme, authors, who wish to build up
their academic profile and publish at all costs, may be
tempted to circumvent the mainstream journals with
tough peer review and to submit their manuscripts to
the so-called predatory journals with no quality control or
soft, decorative peer review (Figure 2). The main aim of
such journals is to sell a space for substandard research
and poorly edited papers and to attract inexperienced au-
thors [13]. Predatory publishers may also claim that they
publish journals that have certain impact indicators, often
calculated by newly launched bogus impact agencies.
Research and academic institutions should take an ac-
tive stance against such journals, and familiarize their
authors with what constitutes a quality and influential
journal and endorse widely acceptable traditional and
alternative impact indicators [14]. One such impact indi-
cator is the h-index, which is universally applicable for
evaluating publication activity and citability of individuals,
academic departments, institutions, and countries. Its bi-
dimensional origin is well fitted with the concept of pub-
lishing citable papers useful for the scientific community.
Authors should be aware of functional characteristics
of online search platforms, bibliographic databases, and
archiving hubs. Open-access publishing provides oppor-
tunities for rapid dissemination of scholarly information.
However, not all online journals are indexed in evidence-
based databases and are capable of properly archiving pa-
pers. Biomedical authors, who wish to address readership,
interested in reading and citing their papers, should target
MEDLINE-indexed journals in the first place. Publishing
in journals indexed in MEDLINE and simultaneously ar-
chived in PubMed Central is an added value as the latter
is an ideal platform for open-access publishing models
and permanent conservation of scholarly information.
Papers archived in PubMed Central can be retrieved
from PubMed and Web of Knowledge search platforms.
However, journal visibility in these platforms differs from
indexing in MEDLINE and Web of Science bibliographic
databases. Publishers should explicitly inform potential
authors about correct indexing and archiving status of
their journals and avoid manipulating and charging for
non-indexed publications.
Exploring options for disseminating scientific ideas in
an ethical and well-informed academic environment is
a big issue for both researchers and publishers [15].
Obviously, educating all stakeholders of scientific com-
munications about effective research reporting, open
archiving and re-using published sources, indexing jour-
nals, and calculating impact indicators is the logical way
out of unethical and flawed publishing environment.Priority of well-checked and edited publications in jour-
nals indexed in relevant databases and web platforms
should become a guiding point for all those who rush to
publish more.
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